https://orcid.org/0000-0002-0635-8041
References
- WHO Fact sheets- Maternal Mortality, 2019; [cited 2021 Nov 02]. Available from: https://www.who.int/news-room/fact-sheets/detail/maternal-mortality.
- Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2:e323–33.
- WHO Recommendations for the prevention and treatment of postpartum haemorrhage. World Health Organization, 2018; [cited 2021 Nov 02]. Available from: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1.
- Carroli G, Cuesta C, Abalos E, et al. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999–1012.
- Widmer M, Piaggio G, Abdel-Aleem H, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials. 2016;17(1):143.
- Gallos ID, Williams HM, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage – a network metaanalysis. Cochrane Database Syst Rev. 2018;4:CD011689.
- (WHO joint statement) WHO/UNICEF/UNFPA joint statement – appropriate storage and management of oxytocin – a Key Commodity for Maternal Health; [cited 2021 Nov 02]. Available from: https://apps.who.int/iris/bitstream/handle/10665/311524/WHO-RHR-19.5-eng.pdf.
- Oxytocin Injection-Clarification of stability data and storage statement requirements; [cited 2021 Nov 02]. Available from: https://extranet.who.int/prequal/sites/default/files/documents/150%20stability%20data%20Oxytocin%20Oct2018.pdf.
- Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15–20.
- Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012;4:CD005457.
- Malm M, Madsen I, Kjellström J. Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and Middle‐income countries. J Pep Sci. 2018;2018:e3082.
- Widmer M, Piaggio G, Nguyen TMH, et al. Heat-Stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;2018:489. [Epub ahead of print].
- Bellad MB, Laxmi BV, Goudar SS, et al. Standardized visual estimation of blood loss during vaginal delivery with its correlation hematocrit changes – a descriptive study. Journal of SAFOG. 2009;1(1):29–34.
- Anger H, Durocher J, Dabash R, et al. How well do postpartum blood loss and common definitions of postpartum haemorrhage correlate with postpartum anaemia and fall in hemoglobin? PLoS One. 2019; 14(8):e0221216.
- Raghavan S, Geller S, Miller S, et al. Misoprostol for primary versus secondary prevention of postpartum haemorrhage: a cluster-randomised non-inferiority community trial. BJOG. 2016;123(1):120–127. Epub 2015 Sep 1.
- Larciprete G, Montagnoli C, Frigo M, et al. Cirese A, and valensise H carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. J Prenat Med. 2013;7(1):12–18.
- Althabe F, Bergel E, Buekens P, et al. Controlled cord traction in the third stage of labor. Systematic review. Int J Gynaecol Obstet. 2006;94(Suppl 2):S126–S127.
- Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up measurements. Bmj. 2001; 323:1123–1124.
- Carvalho JF, Piaggio G, Wojdyla D, et al. Distribution of postpartum blood loss: modeling, estimation and application to clinical trials. Reproductive Health. 2018;15:199.
- Boucher M, Nimrod CA, Tawagi GF, et al. Comparison of carbetocin and oxytocin for the prevention of postpartum haemorrhage following vaginal delivery: a double-blind randomized trial. J Obstet Gynecol Can. 2004;26:481–488.
- Torloni MR, Gomes Freitas C, Kartoglu UH, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016; 123:2076–2086.